Outcomes of treatment with cyclic administration of dienogest after ovarian endometriotic cystectomy

Toru Yanase, Manako Ishida, M. Ishida, Shota Nishijima, Kyoko Morikawa, Tomokazu Yokoo, Y. Takaki, Yoshihiro Takaki, Ikunosuke Tsuneki, Masaki Tamura, Takumi Kurabayashi
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2015 · vol. 31(8) , pp. 643–646 · doi:10.3109/09513590.2015.1032934 · PMID:26291801 · W2288307452
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Cyclic dienogest treatment following ovarian endometriotic cystectomy reduced menstrual pain and cyst recurrence rates, with sustained pain relief for up to 45 months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

To evaluate the outcomes of patients treated with cyclic administration of dienogest after ovarian endometriotic cystectomy, following the completion of treatment. We retrospectively evaluated 26 patients treated with dienogest (2 mg/day) after cystectomy (revised American Society for Reproductive Medicine [r-ASRM] stage III-IV) in a pilot study. Dienogest was administered cyclically, for a total of six cycles, each comprising three weeks on and one week off. Outcomes of interest included severity of menstrual pain and recurrence of cysts at baseline, during the immediate post-treatment period and at the final outpatient follow-up. The mean outpatient follow-up period was 45.0 months. The visual analog scale score for menstrual pain following 6 cycles of dienogest treatment was significantly lower than that at baseline; it remained low at the final follow-up. The recurrence rates of cysts were 4% and 21% at 24 and 48 months after the completion of dienogest treatment, respectively. Six patients with recurrent disease were all classified as having r-ASRM stage IV. Our results suggest that cyclic dienogest for six months after cystectomy could relieve menstrual pain and reduce the recurrence of cysts, for approximately four years. The necessary treatment period for patients with r-ASRM stage IV disease requires further study.

My notes (saved in your browser only)

Condition tags

chronic_pelvic_pain

MeSH descriptors

Antineoplastic Agents, Hormonal Nandrolone Ovarian Cysts Pelvic Pain Adult Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Drug Administration Schedule Female Humans Laparoscopy Nandrolone Nandrolone Nandrolone Ovarian Cysts Pelvic Pain Retrospective Studies Treatment Outcome Young Adult

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (5)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:46.044120+00:00
License: CC0 · commercial use OK